Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3016 in Mild to Moderate Hypertension (China, Phase II)
CTR20260014Phase 2Active
- Sponsor
- SanegeneBio
- Start
- Feb 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3016 in essential hypertension, sponsored by SanegeneBio. Started Feb 2026; status: active.
02
Drugs
IBI3016
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20260014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260014.